ASX Share rice
Wed 12 Aug 2020 - 10:35:am (Sydney)

MYX Share Price

MAYNE PHARMA GROUP LIMITEDMYXPharmaceuticals, Biotechnology & Life Sciences

MYX Company Information

Name:

Mayne Pharma Group Limited

Sector:

Healthcare

Industry:

Drug Manufacturers - Major

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

1538 Main North Road Salisbury South SA Australia 5106

Phone:

61 8 8209 2666

Full Time Employees:

967

MD, CEO & Exec. Director:

Mr. Scott Anthony Richards

Interim CFO & Chief Devel. Officer:

Mr. Peter Paltoglou

Pres of International Operations:

Mr. Stefan J. Cross

VP of Investor Relations & Communications:

Ms. Lisa Pendlebury

Exec. VP & Gen. Counsel:

Ms. Kate Rintoul

Company Overview:

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. It operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The company also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

MYX Share Price Information

Shares Issued:

1.68B

Market Capitalisation:

$612.86M

Revenue (TTM):

$477.99M

Revenue Per Share (TTM):

$0.31

Earnings per Share:

$-0.19

Profit Margin:

-0.6297

Operating Margin (TTM):

$-0.01

Return On Assets (TTM):

$-0

Return On Equity (TTM):

$-0.25

Quarterly Revenue Growth (YOY):

-0.172

Gross Profit(TTM):

$289.94M

Diluted Earnings Per Share (TTM):

$-0.193

MYX CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-91,686,000

Change To Liabilities:

$-30,030,000

Total Cashflow From Investing Activities:

$-91,686,000

Net Borrowings:

$-22,605,000

Net Income:

$-280,866,000

Total Cash From Operating Activities:

$106.61M

Depreciation:

$89.38M

Other Cashflow From Investing Activities:

$-1,000

Change To Inventory:

$-6,430,000

Change To Account Receivables:

$9.43M

Capital Expenditures:

$81.92M

MYX Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-353,717,000

Net Income:

$-280,866,000

Gross Profit:

$301.36M

Operating Income:

$22.44M

Interest Expense:

$17.44M

Income Tax Expense:

$-69,966,000

Total Revenue:

$523.96M

Total Operating Expenses:

$278.92M

Cost Of Revenue:

$222.60M

MYX Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$775.91M

Total Liabilities:

$622.26M

Total Stockholder Equity:

$1.01B

Other Current Liabilities:

$13.92M

Total Assets:

$1.64B

Common Stock:

$1.14B

Other Current Assets:

$398K

Retained Earnings:

$-257,341,000

Other Liabilities:

$92.43M

Good Will:

$21.73M

Other Assets:

$184.09M

Cash:

$89M

Total Current Liabilities:

$211.33M

Short-Term Debt:

$50.86M

Property - Plant & Equipment:

$236.03M

Net Tangible Assets:

$263.51M

Total Current Assets:

$471.95M

Long-Term Debt:

$318.50M

Net Receivables:

$251.68M

Short-Term Investments:

$1.16B

Inventory:

$100.35M

Accounts Payable:

$50.44M

Non Currrent Assets (Other):

$1.16B

Short-Term Investments:

$1.16

Non Current Liabilities (Other):

$59.95M

Non Current Liabilities Total:

$410.93M

MYX Share Price History

MYX News

27 Jul, 2020
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the US Food and Drug Administration (FDA) has granted approval of its Abbreviated New Drug Application (ANDA) for chlorzoxazone tablet, 375 mg, 500 mg and 750 mg, in the United States. Mayne Pharma has commenced commercial launch activities to customers in the US.
21 Jul, 2020
A look at the shareholders of Mayne Pharma Group Limited (ASX:MYX) can tell us which group is most powerful. Insiders...
24 Jun, 2020
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021.
28 May, 2020
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has entered into an exclusive long-term license and supply agreement with Mithra Pharmaceuticals SA (Mithra) to commercialise E4/DRSP, a combined oral contraceptive, in Australia.
22 May, 2020
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of butalbital acetaminophen and caffeine (BAC) capsule 50mg/300mg/40mg in the United States. Mayne Pharma received approval from the US Food and Drug Administration for its Abbreviated New Drug Application, which is indicated for the treatment of tension headache (migraine).
16 Apr, 2020
Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) today announced that Mayne Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for E4/DRSP, a combined oral contraceptive indicated for the prevention of pregnancy. If approved by the FDA, E4/DRSP is expected to be made available to patients in the US market in the first half of calendar 2021.
04 Mar, 2020
Half Year 2020 Mayne Pharma Group Ltd Earnings Presentation
26 Nov, 2019
Full Year 2019 Mayne Pharma Group Ltd Earnings Presentation
03 Nov, 2019
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three...
05 Oct, 2019
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
02 Oct, 2019
ADELAIDE, Australia , Oct. 2, 2019 Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX: MYX) has signed a 20‑year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to ...
05 Sep, 2019
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

MYX Dividend Payments

EX-Date Dividend Amount
2010-10-24$0.0200